Clinical Trial Update: A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB [Phase 1]

View source ↗

Summary

Phase I study assessing safety and immunogenicity of the TB vaccine AERAS-456 in HIV-negative adults treated for drug-susceptible pulmonary tuberculosis; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• AERAS-456

Snippet

Sponsor: Aeras | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED | Results posted: 2019-11-18